Guardian Pharmacy Services, Inc.
GRDNHealthcareNASDAQMedical Care Facilities · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. With a market capitalization of $2.50B, it sits in mid-cap territory. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes.
Market Cap
$2.50B
Beta
0.02
P/E (TTM)
38.29
P/E (Fwd)
27.50
EPS (TTM)
$1.03
EPS (Fwd)
$1.43
ROE
30.4%
ROA
13.5%
Cash
$89.8M
Total Debt
$39.3M
Free CF
$64.5M
52W Change
35.8%
Annual Financials
Cash vs Debt
Where GRDN stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, GRDN finished 0.10% below its 150-day moving average ($39.51) and 4.92% above its 200-day moving average ($37.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GRDN overbought or oversold?
At the October 19, 2026 close, GRDN's RSI(14) was 42.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $89.8M in cash comfortably exceeding the $39.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $64.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 30.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 13.5% further supports the picture of efficient asset utilization. Revenue has grown from $908.9M (2022) to $1.45B (2025), reflecting a 59% increase over the period.
GRDN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing GRDN.